Skip to main content

Advertisement

Table 3 The further anti-tumor therapy following the completion of famitinib or placebo treatment in the full analysis set

From: Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial

Further therapy Famitinib group [cases (%)] (n = 99) Placebo group [cases (%)] (n = 55)
Chemotherapy 21 (21.2) 6 (10.9)
Traditional Chinese medicine 4 (4.0) 4 (7.3)
McAb 0 (0.0) 7 (12.7)
Chemotherapy plus McAb 2 (2.0) 3 (5.5)
Cellular immunotherapy 0 (0.0) 2 (3.6)
Cellular immunotherapy plus chemotherapy 1 (1.0) 0 (0.0)
Targeted therapy 0 (0.0) 1 (1.8)
Radiotherapy 3 (3.0) 2 (3.6)
Radiochemotherapy 1 (1.0) 1 (1.8)
Surgery 2 (2.0) 1 (1.8)
Interventional therapy 2 (2.0) 0 (0.0)
Unspecified 6 (6.1) 2 (3.6)
  1. McAb monoclonal antibody